Shopping Cart
- Remove All
Your shopping cart is currently empty
Ozanimod
Catalog No. T6923Cas No. 1306760-87-1
Alias RPC-1063
Ozanimod (RPC-1063) (RPC1063) is a specific oral S1P Receptor 1 modulator. Ozanimod has been used in trials studying the treatment of Crohn's Disease, Ulcerative Colitis, Multiple Sclerosis, and Relapsing Multiple Sclerosis.
Ozanimod
Catalog No. T6923Alias RPC-1063Cas No. 1306760-87-1
Ozanimod (RPC-1063) (RPC1063) is a specific oral S1P Receptor 1 modulator. Ozanimod has been used in trials studying the treatment of Crohn's Disease, Ulcerative Colitis, Multiple Sclerosis, and Relapsing Multiple Sclerosis.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $41 | In Stock | |
| 5 mg | $97 | In Stock | |
| 10 mg | $147 | In Stock | |
| 25 mg | $297 | In Stock | |
| 50 mg | $478 | In Stock | |
| 100 mg | $690 | In Stock | |
| 200 mg | $977 | In Stock | |
| 500 mg | $1,450 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $97 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Ozanimod"
MP-A08
T16128219832-49-2
MP-A08 is a highly selective, ATP-competitive inhibitor of sphingosine kinase (SPHK1) that targets both SphK1 and SphK2 [Ki: 6.9 ± 0.8 μM and 27 ± 3 μM, respectively].
- $39
Size
QTY
Siponimod
Cited
BAF-312
T64031230487-00-9
BAF312 (Siponimod (BAF-312)), a next-generation S1P receptor modulator, is specific for S1P1 and S1P5 receptors with EC50 of 0.39 nM and 0.98 nM, respectively. The specificity of BAF312 for S1P1 and S1P5 receptors exhibits >1000-fold over S1P2, S1P3 and S1P4 receptors.
- $33
Size
QTY
CitedSiponimod Cited
BAF-312
T64031230487-00-9
BAF312 (Siponimod (BAF-312)), a next-generation S1P receptor modulator, is specific for S1P1 and S1P5 receptors with EC50 of 0.39 nM and 0.98 nM, respectively. The specificity of BAF312 for S1P1 and S1P5 receptors exhibits >1000-fold over S1P2, S1P3 and S1P4 receptors.
- $33
Size
QTY
CitedSiponimod Cited
BAF-312
T64031230487-00-9
BAF312 (Siponimod (BAF-312)), a next-generation S1P receptor modulator, is specific for S1P1 and S1P5 receptors with EC50 of 0.39 nM and 0.98 nM, respectively. The specificity of BAF312 for S1P1 and S1P5 receptors exhibits >1000-fold over S1P2, S1P3 and S1P4 receptors.
- $33
Size
QTY
CitedSiponimod Cited
BAF-312
T64031230487-00-9
BAF312 (Siponimod (BAF-312)), a next-generation S1P receptor modulator, is specific for S1P1 and S1P5 receptors with EC50 of 0.39 nM and 0.98 nM, respectively. The specificity of BAF312 for S1P1 and S1P5 receptors exhibits >1000-fold over S1P2, S1P3 and S1P4 receptors.
- $33
Size
QTY
CitedKi16198
T6347355025-13-7
Ki16198 is an orally available LPA receptor antagonist and is a methyl ester derivative of Ki16425. It inhibits LPA1- and LPA3-induced inositol phosphates with Ki values of 0.34 and 0.93 μM, respectively, and can be used in studies of pancreatic carcinogenesis and metastasis.
- $48
Size
QTY
Ki16198
T6347355025-13-7
Ki16198 is an orally available LPA receptor antagonist and is a methyl ester derivative of Ki16425. It inhibits LPA1- and LPA3-induced inositol phosphates with Ki values of 0.34 and 0.93 μM, respectively, and can be used in studies of pancreatic carcinogenesis and metastasis.
- $48
Size
QTY
Tyloxapol Cited
Triton WR1339
T030725301-02-4
Tyloxapol (Triton WR1339) is a non-ionic liquid polymer utilized as a surfactant.
- $30
Size
QTY
CitedTyloxapol Cited
Triton WR1339
T030725301-02-4
Tyloxapol (Triton WR1339) is a non-ionic liquid polymer utilized as a surfactant.
- $30
Size
QTY
CitedS1PR1 modulator 1
T128212328109-05-1In house
S1PR1 modulator 1 is a selective inhibitor of S1PR1, with a pIC50 of 7.6.
- $59
Size
QTY
Select Batch
Purity:99.74%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | Ozanimod (RPC-1063) (RPC1063) is a specific oral S1P Receptor 1 modulator. Ozanimod has been used in trials studying the treatment of Crohn's Disease, Ulcerative Colitis, Multiple Sclerosis, and Relapsing Multiple Sclerosis. |
| Targets&IC50 | S1P1R:0.41 nM(EC50), S1P5R:11 nM(EC50) |
| In vitro | In S1P1R-HEK293T cells, Ozanimod induces sustained S1P1R internalization and degradation. [1] |
| In vivo | In vivo, Ozanimod shows high oral bioavailability and volume of distribution. In a MOG-induced EAE mouse model, Ozanimod (3 mg/kg, p.o.) suppresses Clinicalal symptoms. In a rat TNBS model of inflammatory bowel disease, Ozanimod (1.2 mg/kg, p.o.) inhibits Clinicalal and histological disease scores. In a Na?ve CD4+CD45Rbhi T cell adoptive transfer model, Ozanimod (1.2 mg/kg, p.o.) also significantly reduced disease severity as assessed by measuring the degree of inflammation, gland loss, hyperplasia, neutrophil infiltrate and mucosal thickness. [1] |
| Alias | RPC-1063 |
| Molecular Weight | 404.46 |
| Formula | C23H24N4O3 |
| Cas No. | 1306760-87-1 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
| Solubility Information | H2O: < 1 mg/mL (insoluble or slightly soluble) DMSO: 16.67 mg/mL (41.21 mM), Sonication is recommended.  Ethanol: 10 mg/mL (24.72 mM) | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
Ethanol/DMSO
| ||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Ozanimod | purchase Ozanimod | Ozanimod cost | order Ozanimod | Ozanimod chemical structure | Ozanimod in vivo | Ozanimod in vitro | Ozanimod formula | Ozanimod molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.